Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).

Authors

Nicholas J. Vogelzang

Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Nicholas J. Vogelzang , Chris Parker , Sten Nilsson , Robert Edward Coleman , Jose Garcia-Vargas , C. Gillies O'Bryan-Tear , Minghua Shan , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Genitourinary Cancers Symposium

bookmark_border

Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

First Author: Sten Nilsson

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.

First Author: Sten Nilsson

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).

First Author: Bertrand F. Tombal

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.

First Author: Steven E. Finkelstein